12:00 AM
 | 
Jul 14, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zohydro ER hydrocodone bitartrate regulatory update

Zogenix said it plans to submit an sNDA to FDA by October for a next-generation of pain drug Zohydro ER hydrocodone capsules designed to make it more difficult to abuse by injection or nasal administration. Next year, Zogenix also said it will to seek to amend the label of the product to include abuse deterrent claims consistent with FDA’s current draft guidance on...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >